Somewhat Favorable News Coverage Likely to Affect Amyris (AMRS) Stock Price

Media coverage about Amyris (NASDAQ:AMRS) has been trending somewhat positive on Tuesday, according to AlphaOne Sentiment Analysis. The research firm, a subsidiary of Accern, identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amyris earned a media sentiment score of 0.19 on AlphaOne’s scale. AlphaOne also gave news headlines about the biotechnology company an impact score of 66 out of 100, meaning that recent media coverage is likely to have an effect on the company’s share price in the next several days.

Here are some of the news headlines that may have impacted Alpha One Sentiment’s rankings:

Separately, Zacks Investment Research raised Amyris from a “sell” rating to a “hold” rating in a research note on Monday, January 16th.

Amyris (NASDAQ:AMRS) traded down 9.4062% during midday trading on Tuesday, hitting $0.2899. The stock had a trading volume of 13,541,067 shares. The company’s 50 day moving average price is $0.50 and its 200-day moving average price is $0.63. Amyris has a 52 week low of $0.28 and a 52 week high of $1.21. The stock’s market capitalization is $80.68 million.

Amyris (NASDAQ:AMRS) last announced its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.05. The company had revenue of $13 million for the quarter, compared to the consensus estimate of $32.30 million. During the same period in the prior year, the firm posted ($0.17) EPS. The firm’s revenue was up 47.7% compared to the same quarter last year. Equities analysts anticipate that Amyris will post ($0.25) earnings per share for the current fiscal year.

In other news, major shareholder (Mauritius) Pte Ltd Maxwell sold 652,513 shares of the business’s stock in a transaction on Thursday, April 20th. The shares were sold at an average price of $0.55, for a total transaction of $358,882.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders sold 8,570,081 shares of company stock valued at $4,529,961. 48.70% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Likely to Affect Amyris (AMRS) Stock Price” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

5 Day Chart for NASDAQ:AMRS

What are top analysts saying about Amyris Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amyris Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit